

Screening of Insulin (*INS*) Gene in Permanent Neonatal Diabetes During The First Year of Life

Thesis

Submitted for Partial Fulfillment of
M.Sc. Degree in Clinical and Chemical Pathology

By

Aisha Omar Mohamed Atef Tolba

M.B,B.Ch, Faculty of Medicine, Cairo University

Under Supervision of

Dr. Nadida Abdelhamid Gohar

Professor of Clinical and Chemical Pathology
Faculty of Medicine, Cairo University

Dr. Walaa Ahmed Mohamed Rabie

Lecturer of Clinical and Chemical Pathology
Faculty of Medicine, Cairo University

Dr. Marwa Farouk Mira

Lecturer of Pediatrics
Faculty of Medicine, Cairo University

Faculty of Medicine

Cairo University

2014

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

ACKNOWLEDGMENTS

*I would like to express my deep gratitude to my **Professor Dr. Nadida Abdelhamid Gohar**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, under whose supervision I had the honour to proceed with this work. Her persistent encouragement, help and supervision were the main push in initiating and completing this work.*

*I am grateful to **Dr. Walaa Ahmed Mohamed Rabie**, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, for her constant support and meticulous revision that have been of utmost help in performing this work, all that with unlimited generosity in time and effort.*

*I wish to express my appreciation to **Dr. Marwa Farouk Mira**, Lecturer of Pediatrics, Faculty of Medicine, Cairo University, who gave me great help in this work.*

*I do feel highly indebted to **Professor Dr. Sahar Abdel-Atty Sharaf**, Professor of Clinical and Chemical Pathology, Cairo University, for her generous help, constant support, valuable remarks and indispensable role in initiating and completing this work.*

*I would especially like to thank to **Dr. Marwa Mahmoud Abdel-Aziz Alsharkawy**, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, whose technical knowledge and scientific expertise were of significant aid to the achievement of that work.*

*I will always be grateful to **my professors and colleagues** for their support and encouragement.*

*My gratitude to **my family** for their patience and continuous encouragement.*

*Last but not the least my appreciation and thanks are due to my **little patients** and **their families** without whom this work would have never been conducted.*

Abstract

Background: Permanent neonatal diabetes (PND) is a monogenic form of diabetes resulting from mutations in a number of different genes encoding proteins that play a key role in the normal function of the pancreatic beta-cell. A correct genetic diagnosis can affect treatment and clinical outcome. Mutations in the insulin gene (*INS*) itself have been identified as a cause of neonatal diabetes. This study aimed to investigate the genetic variations in the coding region and intronic boundaries of *INS* gene and their genotype phenotype correlation in a group of Egyptian PNDM infants with onset in the first 12 months of age.

Methods: We screened exons 2 and 3 with intronic boundaries of *INS* gene by direct gene sequencing in 30 PND patients (14 males and 16 females) and in 20 healthy control subjects to verify the resulting single nucleotide polymorphisms (SNPs). A detailed clinical phenotyping of the patients was carried out to specify the diabetes features in those found with an *INS* variant.

Results: We identified five variants (four SNPs and one silent mutation), c.187+11T>C, c.-17-6T>A, c.*22A>C, c.*9C>T and c.36G>A (p.A12A) with allelic frequency of 96.7%, 80%, 75%, 5% and 1.7%, respectively. All showed no statistically significance difference compared to the controls except for c.*22A>C.

Conclusion: Genetic screening for the *INS* gene did not reveal any evident role in diagnosis of PNDM among the studied group of Egyptian children.

Keywords: Permanent neonatal diabetes (PND); *INS*; mutations; DNA sequencing

List of Contents

	Page
List of Abbreviations	i
List of Tables	iii
List of Figures	iv
Introduction and Aim of the Work	1
Review of Literature	
Chapter 1: Permanent Neonatal Diabetes Mellitus	3
Chapter 2: Insulin (<i>INS</i>) Gene	25
Chapter 3: Insulin gene mutations and Permanent Neonatal Diabetes Mellitus	35
Chapter 4: DNA sequencing	42
Subjects and Methods	58
Results	85
Discussion	93
Summary and Conclusion	99
Recommendations	100
References	101
Appendices	114
Arabic summary	

List of Abbreviations

<i>ABCC8</i>	ATP-binding cassette transporter subfamily C, member 8
AD	Autosomal dominant
APS	Adenosine 5'phosphosulfate
AR	Autosomal recessive
CBP	Creb-binding protein
CCD	Charge coupled device
ddNTP	Dideoxynucleotide
DEND	Developmental delay, Epilepsy and Neonatal Diabetes
DKA	Diabetic ketoacidosis
DMR	Differentially methylated region
dNTP	Deoxynucleotide
<i>EIF2AK3</i>	Eukaryotic translation Initiation Factor 2 Alpha kinase 3
ERAD	Endoplasmic reticulum associated degradation
<i>FOXP3</i>	Forkhead box P3
<i>GCK</i>	Glucokinase gene
GAD	Glutamate decarboxylase
<i>GLIS</i>	Glioma-associated oncogene similar
GlisBS	Glis binding site
GLUT2	Glucose transporter 2
GWAS	Genome wide association studies
HCR	Hydrophobic core region
HGVS	Human Genome Variation Society
HIL	Hypomethylation at imprinted loci
<i>HYMAI</i>	Hydatiform mole-associated and imprinted
IA-2A	Islet antigen-2 antibody
IC	Imprinting center
IDDM2	Insulin dependent diabetes mellitus 2
ILPR	Insulin-linked polymorphic region
<i>INS</i>	Insulin gene
IPEX	Immune dysregulation, Polyendocrinopathy, and Enteropathy, X-linked syndrome
<i>IPF1</i>	Insulin Promoter Factor-1
IRDN	Insulin-related DNA polymorphism
IUGR	Intra-uterine growth retardation
IVS	Intervening sequences

K_{ATP}	ATP-sensitive potassium channel
KCNJ11	Potassium inwardly-rectifying channel, subfamily J, member 11
Kir	Inwardly rectifying potassium channels
MafA	v-maf musculoaponeurotic fibrosarcoma oncogene homolog A
MDI	Monogenic diabetes of infancy
MODY	Maturity onset diabetes of the young
NCBI	National Centre of Biotechnology Information
NDM	Neonatal Diabetes Mellitus
NEUROD1	Neurogenic differentiation 1
NGS	Next-generation sequencing
PCR	Polymerase Chain Reaction
PDX1	Pancreas/ duodenum homeobox protein 1
PGD	Pre-implantation genetic diagnosis
PLAGL1	Pleomorphic adenoma of the salivary gland gene like 1
PNDM	Permanent Neonatal Diabetes Mellitus
PPI	pyrophosphate
PTF1A	Pancreas transcription factor 1A
RFX	Regulatory factor X-box binding family
SGA	Small for gestational age
SLC2A2	Solute carrier family member 2
SLC19A2	Solute carrier family 19 member 2
SNPs	Single nucleotide polymorphisms
SOLiD	Sequencing by Oligo Ligation Detection
SP	Signal peptide
SUR	Sulfonylurea receptor
TNDM	Transient Neonatal Diabetes Mellitus
T1DM	Type 1 Diabetes Mellitus
T2DM	Type 2 Diabetes Mellitus
UPD	Uniparental disomy
UTR	Untranslated region
VNTR	Variable number tandem repeat
WRS	Wolcott-Rallison syndrome
ZAC	Zinc finger protein which regulates apoptosis and cell cycle
ZFP57	Zinc finger protein 57
ZMWs	Zero-mode waveguides

List of Tables

	Page
Table 1: Genotype/ phenotype relationship in PNDM	19
Table 2: Insulin gene mutations and diabetes	40
Table 3: Comparison of Next and Next Next generation platforms	48
Table 4: The nomenclature of amino acids	57
Table 5: Forward and Reverse Primers sequence for exons 2 and 3 of <i>INS</i> gene	65
Table 6: Demographic characteristics of studied cases	85
Table 7: Clinical and laboratory characteristics of studied cases	86
Table 8: Genotype distribution of c.-17-6T>A variant among cases and control group	87
Table 9: Genotype distribution of c.187+11T>C variant among cases and control group	87
Table 10: Genotype distribution of c.36G>A variant among cases and control group	88
Table 11: Genotype distribution of c.*22A>C variant among cases and control group	89
Table 12: Genotype distribution of c.*9C>T variant among cases and control group	89
Table 13: Genotype distribution of combined variants of exon 2 c.-17-6T>A and c.187+11T>C, respectively among cases and control group	90
Table 14: Allele distribution of c.-17-6T>A variant among cases and control group	91
Table 15: Allele distribution of c.187+11T>C variant among cases and control group	91
Table 16: Allele distribution of c.36G>A variant among cases and control group	91
Table 17: Allele distribution of c.*22A>C variant among cases and control group	92
Table 18: Allele distribution of c.*9C>T variant among cases and control group	92

List of Figures

	Page
Figure 1: Schematic representation of paternal uniparental disomy (UPD) of chromosome 6	8
Figure 2: Three different genetic mechanisms cause 6q24-TNDM	9
Figure 3: Schematic representation of the octameric K _{ATP} channel complex viewed in cross section	11
Figure 4: (A) Insulin secretion in relation to the potassium channel encoded for by <i>KCNJ11</i> and <i>ABCC8</i> in a normal subject (B) Heterozygous activating mutations in the <i>KCNJ11</i> and <i>ABCC8</i> genes cause PNDM	12
Figure 5: Pancreatic beta-cell genes known as targets of monogenic diabetes	18
Figure 6: Clinical subtypes of permanent neonatal diabetes mellitus and their management	24
Figure 7: The location of <i>INS</i> gene on chromosome 11	25
Figure 8: Synthesis of insulin	27
Figure 9: Post-translational modification of preproinsulin to biologically-active insulin	28
Figure 10: Three key transcription factors that bind within promotor region	29
Figure 11: Insulin VNTR minisatellite repeats in insulin promoter area	30
Figure 12: The ER stress response pathway	31
Figure 13: (A) DNA sequences of the <i>INS</i> mutations c.137G>A (R46Q) and c.163C>T (R55C) found in the Norwegian MODY Registry and the Norwegian Childhood Diabetes Registry, respectively (B) Location of the two corresponding amino acid substitutions in the preproinsulin molecule	33
Figure 14: Schematic representation of the intron-exon structure of the <i>INS</i> gene and the splicing changes due to the found mutation	38
Figure 15: Electropherogram for c.188-31G>A variant of <i>INS</i> gene ...	38
Figure 16: Electropherogram for c.38T>G (p.L13R) heterozygous <i>INS</i> mutation and the normal DNA sequence for comparison	39
Figure 17: Diagrammatic representation of the amino acid sequence of human preproinsulin	41

Figure 18:	Diagrammatic representation of the structure of dideoxynucleotide (ddNTP) and deoxynucleotide (dNTP)	43
Figure 19:	Manual sequencing using radiolabeled ddNTPs	44
Figure 20:	Schematic representation of a capillary-based DNA sequencing system	44
Figure 21:	Next and Next Next generation sequencing different platforms	47
Figure 22:	(A) Cost per Megabase of DNA Sequence (B) Cost per Genome	49
Figure 23:	Clonal amplification of sequencing features. (A) Emulsion PCR (B) Bridging amplification	51
Figure 24:	Schematic representation showing sequencing during synthesis using 3'- O blocking reversible terminators.....	52
Figure 25:	Pyrosequencing chemistry: biochemical reactions and enzymes involved in the generation of light signals by DNA pyrosequencing	53
Figure 26:	Sequencing-by-ligation, using the SOLiD DNA sequencing platform	54
Figure 27:	Principle of nucleic acid extraction	60
Figure 28:	DNA extraction kit QIAamp®	61
Figure 29:	QIAamp® Spin Procedure	63
Figure 30:	The exponential amplification of the gene in PCR	64
Figure 31:	BIO RAD T100™ Thermal Cycler	66
Figure 32:	Amplification program for both exon 2 and exon 3	67
Figure 33:	The amplified products of exon 2 and exon 3	70
Figure 34:	QIAquick® PCR Purification Kit	70
Figure 35:	The QIAquick® spin column and 2 ml collection tube	71
Figure 36:	The QIAquick purification Procedure	72
Figure 37:	Purified DNA appears as single bands on the gel	72
Figure 38:	Cycle Sequencing program	74
Figure 39:	Diagram of dye terminator Cycle Sequencing	74
Figure 40:	(A) Centri-Sep column before hydration (B) Centri-Sep column after addition of 800 µl of nuclease free water	76
Figure 41:	Application of the completed DyeDeoxy terminator reaction mixture	76
Figure 42:	Four bases detected and distinguished in one capillary injection	77

Figure 43:	Capillary array: 8 capillaries/ array	78
Figure 44:	POP-7 polymer pouch	78
Figure 45:	96-well plate Retainer and Base Set	78
Figure 46:	The ABI 3500 Genetic Analyzer and the ABI 310 Genetic Analyzer	78
Figure 47:	Chromatogram shows c.-17-6T>A heterozygous, c.36 G>A heterozygous and c.187+11T>C homozygous in exon 2 of <i>INS</i> gene, respectively in the cases	80
Figure 48:	Chromatogram shows c.-17-6T>A heterozygous and c.187+11T>C heterozygous in exon 2 of <i>INS</i> gene, respectively in the cases	81
Figure 49:	Chromatogram shows c.-17-6T>A heterozygous and c.187+11T>C homozygous in exon 2 of <i>INS</i> gene, respectively in the controls	82
Figure 50:	Chromatogram shows c.*9C>T heterozygous and c.*22A>C heterozygous in exon 3 of <i>INS</i> gene, respectively in the cases	83
Figure 51:	Chromatogram shows c.*22 A>C heterozygous in exon 3 of <i>INS</i> gene in the controls	84
Figure 52:	c.-17-6T>A variant in exon 2 of <i>INS</i> gene (A) TT genotype (B) TA genotype (C) AA genotype	87
Figure 53:	c.187+11T>C variant in exon 2 of <i>INS</i> gene (A) TC genotype (B) CC genotype	88
Figure 54:	c.36G>A variant in exon 2 of <i>INS</i> gene (A) GG genotype (B) GA genotype	88
Figure 55:	c.*22A>C variant in exon 3 of <i>INS</i> gene (A) AA genotype (B) AC genotype (C) CC genotype	89
Figure 56:	c.*9C>T variant in exon 3 of <i>INS</i> gene (A) CC genotype (B) CT genotype	90

Introduction

Monogenic diabetes is a heterogeneous group of disorders characterized most often by pancreatic beta-cell dysfunction as a result of a single gene mutation. Monogenic subtypes include neonatal diabetes that is either permanent or transient (PNDM/TNDM) and maturity onset diabetes of the young (MODY) (*Rubio-Cabezas and Argente, 2008; Edghill et al., 2010; and Schwitzgebel, 2014*).

Over the last decade the insight into the causes of neonatal diabetes has greatly expanded. Neonatal diabetes was once considered a variant of type 1 diabetes that presented early in life. Studies in understanding of this disorder have established that neonatal diabetes is not an autoimmune disease, but rather is a monogenic form of diabetes resulting from mutations in a number of different genes encoding proteins that play a key role in the normal function of the pancreatic beta-cell (*Stoy et al., 2010; and American Diabetes Association, 2014*).

Mutations in the genes encoding the ATP-sensitive potassium channel (K_{ATP}) subunits [Potassium inwardly rectifying channel, subfamily J, member 11 (*KCNJ11*) encoding Kir6.2, ATP-binding cassette transporter subfamily C member 8 (*ABCC8*) encoding *SUR1*] and in the gene encoding insulin (*INS*) account for most cases of PNDM/monogenic diabetes of infancy [MDI] (*Russo et al., 2011; and American Diabetes Association, 2014*).

As in monogenic diabetes a single gene mutation decides about the disease phenotype, it is possible to establish a specific diagnosis based on a DNA analysis in a considered patient. The search for a mutation is typically performed by automated sequencing. Making such a diagnosis usually has significant clinical importance as it may influence diabetes treatment, explain pleiotropic features and define the prognosis in the

examined subject as well as in other family members (*Ellard et al., 2008; and Rubio-Cabezas et al., 2011*).

Aim of the work

This study aimed to investigate the genetic variations in the coding region and intronic boundaries of *INS* gene and their genotype phenotype correlation in a group of Egyptian PNDM infants with onset in the first 12 months of age.

Chapter 1

Permanent Neonatal Diabetes Mellitus

Neonatal diabetes (ND) is a monogenic form that is usually defined as overt diabetes diagnosed during the first 6 months of life (*Hussain et al., 2013*). The disease can be clinically subdivided into transient (TNDM) and permanent (PNDM) forms depending on whether or not insulin dependence resolves in infancy (*Garin et al., 2012*).

Monogenic diabetes is a result of a single gene mutation at different allelic loci and does not involve an environmental component in disease formation as with polygenic forms (*Rubio-Cabezas and Argente, 2008*). PNDM is caused by mutations affecting genes that play a critical role in the development, survival and function of pancreatic β -cells (*Miki et al., 2001; and Rubio-Cabezas et al., 2011*).

Incidence of PNDM

PNDM is a rare condition with a reported incidence of approximately 1: 200,000 births in Caucasian populations (*De Franco et al., 2013*).

Diagnosis of PNDM

Neonatal diabetes mellitus presents as hyperglycemia, failure to thrive and, in some cases, dehydration and ketoacidosis, which may be severe with coma in a child within the first months of life (*Polak and Cavé, 2007*).

Almost two-thirds of the infants diagnosed in the first 6 months were born small for gestational age (SGA), in contrast to 15% of those presenting later (*Iafusco et al., 2002*). Because insulin exerts potent growth-promoting effects during intrauterine development (*Gicquel and Le Bouc, 2006*), a low birth weight might reflect reduced insulin secretion by the fetal pancreas suggesting a more precocious damage to